Trials / Completed
CompletedNCT04071262
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer
A Phase 1 Study of Abemaciclib in Combination With Other Anti-Cancer Therapy in Japanese Patients With Advanced Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Male
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if the study drug abemaciclib in combination with other anti-cancer therapies is safe in Japanese participants with advanced cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abemaciclib | Administered orally |
| DRUG | Abiraterone Acetate | Administered orally |
| DRUG | Prednisolone | Administered orally |
Timeline
- Start date
- 2019-12-20
- Primary completion
- 2021-02-12
- Completion
- 2021-08-30
- First posted
- 2019-08-28
- Last updated
- 2021-09-21
Locations
2 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04071262. Inclusion in this directory is not an endorsement.